220651-94-5
Chemical Structure
Ruplizumab
Synonym(s): BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8
- CAS No.: 220651-94-5
- Formula:N/A
- Molecular Weight:(145.68 kDa)
SMILES: [Ruplizumab]
Biological Activity: Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ruplizumab | 99.84% | Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chris Chamberlain, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017 Nov;76(11):1837-1844. [Content Brief]
- [2]. Law C L, et al. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Therapeutic targets of the TNF superfamily, 2009: 8-36.
Keywords
